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Background
Several studies have shown that both FGF19 mRNA and
protein are widely distributed in human tissues where
they play an important role in cell proliferation, differ-
entiation and motility (1-3). As part of our systematic
search for prognostic markers in breast cancer (BC), the
present study was conducted to assess the prognostic
value of FGF19 in patients with BC.
Materials and methods
Archival FFPE tumor samples were analyzed using
immunohistochemistry (IHC) for monoclonal anti-
FGF19 (W12) antibody in 193 patients with BC. IHC
analysis was done using the automatic system (Bench-
Mark XT; Ventana Medical Systems, Inc. Tucson, AZ,
USA). Patients were diagnosed and treated at the
Departments of Pathology, Surgery and Oncology, King
Abdulaziz University Hospital, Saudi Arabia and the
National Oncology Institute, Sabratha, Libya during
years 2000-2008.
Results
The expression pattern of FGF19 was predominantly
cytoplasmic in the tumor area. Of the 193 tumors, 40%
were considered low FGF19 expression, whereas 60%
were considered high FGF19 expression. Interestingly, in
lymph node positive patients, there was highly signifi-
cant correlation between FGF19 expression and age of
patients (p=0.008). Moreover, FGF19 expression showed
significant correlation with tumor recurrence (p=0.02).
Interestingly, in univariate (Kaplan-Meier) survival analysis,
FGF19 expression was differentiating the DSS of lymph
node positive tumors more significantly than the lymph
node negative tumors (p<0.0001, log rank), in that tumors
of lymph node positive patient with high FGF19 expression
was more often, who eventually died of their disease
(shorter disease specific survival (DSS)) as compared with
those who were alive at the completion of the follow-up.
On the other hand, PR status, tumor stage and grade had
no significant relationship with FGF19 expression.
Conclusions
Quantification of FGF19 expression seems to provide valu-
able prognostic information in BC, particularly in selecting
lymph node positive patients who are at high risk for
shorter DSS who might benefit from targeted therapy.
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